| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 03/07/2013 | US20130058960 Compositions and methods for the diagnosis and treatment of tumor |
| 03/07/2013 | US20130058959 Hematopoietic cell selectin ligand polypeptides and methods of use thereof |
| 03/07/2013 | US20130058958 Compositions and methods useful for reducing the viscosity of protein-containing formulations |
| 03/07/2013 | US20130058957 Dendritic cell immunoreceptor agonist |
| 03/07/2013 | US20130058956 Extracellular ifi16 as therapeutic agents |
| 03/07/2013 | US20130058955 Anti-polyubiquitin antibodies and methods of use |
| 03/07/2013 | US20130058954 Diagnostic and therapeutic methods for corneal ectasia following refractive surgery, keratoconus or pellucid degeneration |
| 03/07/2013 | US20130058953 Characterization of the cbir1 antigenic response for diagnosis and treatment of crohn's disease |
| 03/07/2013 | US20130058952 Anti-hsv antibody |
| 03/07/2013 | US20130058951 Anti-s1p antibody treatment of patients with ocular disease |
| 03/07/2013 | US20130058950 Methods for detecting progenitor cells and uses thereof |
| 03/07/2013 | US20130058949 Antagonists of il-6 to prevent or treat thrombosis |
| 03/07/2013 | US20130058948 Antibodies Directed To Gpnmb And Uses Thereof |
| 03/07/2013 | US20130058947 Novel Modulators and Methods of Use |
| 03/07/2013 | US20130058946 Seizure and Migraine Treatments using Denosumab |
| 03/07/2013 | US20130058945 Antigenic GM-CSF Peptides and Antibodies to GM-CSF |
| 03/07/2013 | US20130058944 Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9) |
| 03/07/2013 | US20130058943 Bovine polyclonal antibody specific for human tnf |
| 03/07/2013 | US20130058942 Human beta-adrenergic receptor kinase polypeptide and methods |
| 03/07/2013 | US20130058941 Monoclonal antibodies and binding fragments thereof directed to the melanocortin-4 receptor and their use in the treatment of cachexia and related conditions and diseases |
| 03/07/2013 | US20130058940 Novel Gene And Protein Associated With Angiogenesis And Endothelial Cell Specific Apoptosis |
| 03/07/2013 | US20130058939 Treatment of neurological or neurodegenerative disorders |
| 03/07/2013 | US20130058938 Gna11 mutations in melanoma |
| 03/07/2013 | US20130058937 Bispecific antigen binding molecules |
| 03/07/2013 | US20130058936 Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use |
| 03/07/2013 | US20130058935 Antibodies to tumor endothelial marker 7r |
| 03/07/2013 | US20130058934 Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies |
| 03/07/2013 | US20130058933 Monovalent ligands of the human cd28 receptor |
| 03/07/2013 | US20130058932 Use of pkc-iota inhibitors for the treatment of glioma |
| 03/07/2013 | US20130058931 Methods of predicting and decreasing the risk of pregnancy loss |
| 03/07/2013 | US20130058930 Subcutaneous needle assisted jet injection administration of methotrexate |
| 03/07/2013 | US20130058929 Fusion proteins for inhibition and dissolution of coagulation of thrombi |
| 03/07/2013 | US20130058928 Hair growth methods using fgfr3 extracellular domins |
| 03/07/2013 | US20130058927 Anti-vegf antibodies |
| 03/07/2013 | US20130058926 Method for alleviating and/or preventing skin reddening |
| 03/07/2013 | US20130058925 Epithelial biomarkers for cancer prognosis |
| 03/07/2013 | US20130058924 Hypoxia-related gene signatures for cancer classification |
| 03/07/2013 | US20130058923 Biomolecular interactions and interaction products as biomarkers for detection, diagnosis, prognosis and predicting therapeutic responses of human diseases |
| 03/07/2013 | US20130058922 Pharmaceutical composition containing choline |
| 03/07/2013 | US20130058921 Use of autologous effector cells and antibodies for treatment of multiple myeloma |
| 03/07/2013 | US20130058920 METHODS FOR IMPROVING THE BIOACTIVITY OF THERAPEUTIC IgE ANTIBODIES FOR THE TREATMENT OF DISEASE |
| 03/07/2013 | US20130058919 Optimized Fc Variants and Methods for their Generation |
| 03/07/2013 | US20130058918 Isolation and use of a new type of glial cell with neurotoxic potential |
| 03/07/2013 | US20130058917 Antibody composition obtained by fractionation of plasma immunoglobulins affinity chromatography on a sambucus nigra affinity column |
| 03/07/2013 | US20130058915 Methods and compositions for treatment of angelman syndrome and autism spectrum disorders |
| 03/07/2013 | US20130058914 Genetic polymorphisms associated with coronary events and drug response, methods of detection and uses thereof |
| 03/07/2013 | US20130058894 Therapeutic protein-specific induced tolerogenic dendritic cells and methods of use |
| 03/07/2013 | US20130058893 Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof |
| 03/07/2013 | US20130058891 Kexin-Derived Vaccines to Prevent or Treat Fungal Infections |
| 03/07/2013 | US20130058869 Prevention And Treatment Of Amyloidogenic Disease |
| 03/07/2013 | US20130058868 Method for the treatment of t cell mediated conditions by depletion of icos-positive cells in vivo |
| 03/07/2013 | US20130058864 Antibodies that bind ov064 and methods of use therefor |
| 03/07/2013 | CA2847442A1 Mycobacterium tuberculosis porins and toxins and related methods |
| 03/07/2013 | CA2847332A1 Vaccine preparation for cancer treatment |
| 03/07/2013 | CA2847263A1 Influenza virus antibody compositions |
| 03/07/2013 | CA2847204A1 Adjuvanted formulations of staphylococcus aureus antigens |
| 03/07/2013 | CA2847115A1 Nucleic acid construct comprising nucleic acid derived from genome of hepatitis c virus of genotype 3a |
| 03/07/2013 | CA2847020A1 Caninised tumour necrosis factor antibodies and methods of using the same |
| 03/07/2013 | CA2846858A1 Methods for effectively and rapidly desensitizing allergic patients |
| 03/07/2013 | CA2846290A1 Engineered sequences to facilitate expression of antigens in neisseria and methods of use |
| 03/07/2013 | CA2846248A1 Method for inhibiting cellular activation by insulin-like growth factor-1 |
| 03/07/2013 | CA2846043A1 Pegylated liposomes for delivery of immunogen-encoding rna |
| 03/07/2013 | CA2844898A1 Use of the pacap as a molecular adjuvant for vaccines |
| 03/06/2013 | EP2565275A1 Method of treatment of vascular complications using modulators of TRX and TRXNIP |
| 03/06/2013 | EP2565268A1 Novel muc1 antibody |
| 03/06/2013 | EP2565207A2 Humaneered Anti-Factor B Antibody |
| 03/06/2013 | EP2565204A1 Novel immunogenic epitopes for immunotherapy |
| 03/06/2013 | EP2565203A1 Peptide vaccines having Seq ID: 344v for cancers expressing tumor-associated antigens |
| 03/06/2013 | EP2565201A1 WT1 HLA class II-binding peptides and compositions and methods comprising same |
| 03/06/2013 | EP2564870A1 Pharmaceutical composition for treatment and prevention of herpesvirus infections |
| 03/06/2013 | EP2564869A1 Synthetic capsid proteins and uses thereof |
| 03/06/2013 | EP2564868A1 Attenuated Mycoplasma Gallisepticum strains |
| 03/06/2013 | EP2564867A1 Autologous biological cancer vaccine |
| 03/06/2013 | EP2564846A1 Methods of treating hematologic cancers using pnp inhibitors such as forodesine in combination with anti-cd20 agents |
| 03/06/2013 | EP2563923A2 Compositions and methods for reduced scarring and for treatment of fibrosis |
| 03/06/2013 | EP2563813A1 Anti-c5a antibodies and methods for using the antibodies |
| 03/06/2013 | EP2563810A1 Recombinant single-chain antibody fragment neutralizing the cytolytic activity of vaginolysin |
| 03/06/2013 | EP2563398A1 Growth hormone receptor deficiency causes a major reduction in pro-aging signaling, cancer and diabetes in humans |
| 03/06/2013 | EP2563397A2 Sparc binding aptamers and uses thereof |
| 03/06/2013 | EP2563396A2 Delivery proteins |
| 03/06/2013 | EP2563395A2 Anti-s1p antibody treatment of patients with ocular disease |
| 03/06/2013 | EP2563394A2 Methods and compositions for treating celiac disease |
| 03/06/2013 | EP2563393A1 Sparc binding antibodies and uses thereof |
| 03/06/2013 | EP2563392A1 Detection and modulation of slit and roundabount (robo) mediated lymph vessel formation and uses thereof |
| 03/06/2013 | EP2563391A1 Combination therapy of an afucosylated cd20 antibody with a mtor inhibitor |
| 03/06/2013 | EP2563390A2 Methods and articles for preventing or reducing risk of developing a hyperallergenic immune system |
| 03/06/2013 | EP2563389A1 Universal vaccine against h5n1 lineages |
| 03/06/2013 | EP2563388A1 Parapoxvirus expressing the vp60 major capsid protein of the rabbit haemorrhagic disease virus |
| 03/06/2013 | EP2563387A1 Adenovirus vaccine vectors |
| 03/06/2013 | EP2563386A1 Vaccination method using microneedle arrays |
| 03/06/2013 | EP2563384A2 Immunogenic compositions and methods for treating neoplasia |
| 03/06/2013 | EP2563383A2 Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of valyl trna synthetases |
| 03/06/2013 | EP2563382A2 Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of threonyl trna synthetases |
| 03/06/2013 | EP2563381A2 Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of isoleucyl trna synthetases |
| 03/06/2013 | EP2563380A2 Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-trna synthetase |
| 03/06/2013 | EP2563316A1 Methods, articles and kits for allergic desensitization via the oral mucosa |
| 03/06/2013 | EP1524993B1 Neisserial vaccine compositions comprising a combination of antigens |
| 03/06/2013 | CN102959082A New compositions and methods for treatment of autoimmune and allergic diseases |
| 03/06/2013 | CN102958942A Heterodimer binding proteins and uses thereof |
| 03/06/2013 | CN102958941A Compositions and methods for the diagnosis and treatment of tumor |